Scientific Opinion on the substantiation of a health claim related to Yestimun® and defence against pathogens in the upper respiratory tract pursuant to Article 13(5) of Regulation (EC) No 1924/2006

EFSA Journal

Volumn 11, Issue 4, 2013, Pages

[No Author Info available]

Author keywords

beta glucans; brewer's yeast; health claims; pathogens; upper respiratory tract; Yestimun

Indexed keywords

EID: 84923026001     PISSN: None     EISSN: 18314732     Source Type: Journal    
DOI: 10.2903/j.efsa.2013.3159     Document Type: Article

References (24)

1. Akramiene D, Kondrotas A, Didziapetriene J and Kevelaitis E, 2007. Effects of beta-glucans on the immune system. Medicina (Kaunas), 43, 597–606.
2. Bohn JA and BeMiller JN, 1995. (1→3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydrate Polymers, 28, 3–14.
3. Bothe G, 2011, unpublished. Double-blind, randomized, placebo-controlled clinical study to evaluate efficacy and safety of Yestimun® in subjects with increased susceptibility to common cold.
4. Brown GD and Gordon S, 2005. Immune recognition of fungal beta-glucans. Cellular Microbiology, 7, 471–479.
5. Döll M, Hauss R and Spermezan R, 2005. Anwendungsbeobachtung: Immunmodulierende Wirkung von (1–3),(1–6)- -D-Glucan – Gezeigt an der Neopterin- und b-Defensin-Synthese. Naturheilpraxis, 5.
6. Feldman S, Schwartz HI, Kalman DS, Mayers A, Kohrman HM, Clemens R and Krieger DR, 2009. Randomized phase II clinical trials of Wellmune WGP® for immune support during cold and flu season. The Journal of Applied Research, 9, 30–42.
7. Fleischer LG, Gerber G, Liezenga RW, Lippert E, Scholl MA and Westphal G, 2000. Blood cells and plasma proteins of chickens fed a diet supplemented with (1–>3),(1–>6)-beta-D-glucan and enrofloxacin. Archiv für Tierernährung, 53, 59–73.
8. Fleischer LG, Gerber G, Gremmels HD, Lippert E and Westphal G, 2001. Experimentelle Modelluntersuchungen zum Einsatz von (1–>3),(1–>6)-beta-D-Glucan aus Saccharomyces cerevisiae als “Health Ingredient”. Fibiona Health Products GmbH.
9. Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP and Underhill DM, 2011. Activation of the innate immune receptor Dectin-1 upon formation of a ‘phagocytic synapse’. Nature, 472, 471–475.
10. Graubaum HJ, 2007, unpublished. Double-blind, randomized, placebo-controlled, multicentric nutrition study to prove the efficacy and safety of Biolex® Beta HP as a prophylactic and therapeutic for common colds.
11. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK and Ross GD, 2004. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. Journal of Immunology, 173, 797–806.
12. Jackson GG, Dowling HF, Spiesman IG and Boand AV, 1958. Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Archives of Internal Medicine, 101, 267–278.
13. Kankkunen P, Teirilä L, Rintahaka J, Alenius H, Wolff H and Matikainen S, 2010. (1,3)-beta-glucans activate both dectin-1 and NLRP3 inflammasome in human macrophages. Journal of Immunology, 184, 6335–6342.
14. Kogan G, 2000. (1→3,1→6)-β-D-glucans of yeasts and fungi and their biological activity. In: Studies in Natural Products Chemistry, Volume 23: Bioactive natural Products (Part D). Ed Atta-ur-Rahman. Elsevier, Amsterdam, NL, 107–152.
15. Lehne G, Haneberg B, Gaustad P, Johansen PW, Preus H and Abrahamsen TG, 2006. Oral administration of a new soluble branched beta-1, 3-D-glucan is well tolerated and can lead to increased salivary concentrations of immunoglobulin A in healthy volunteers. Clinical and Experimental Immunology, 143, 65–69.
16. Li J, Xing J, Li D, Wang X, Zhao L, Lv S and Huang D, 2005. Effects of beta-glucan extracted from Saccharomyces cerevisiae on humoral and cellular immunity in weaned piglets. Archives of Animal Nutrition, 59, 303–312.
17. Małaczewska J, Wójcik R, Jung L and Siwicki AK, 2010. Effect of Biolex β-HP on selected parameters of specific and non-specific humoral and cellular immunity in rats. Bulletin of the Veterinary Institute in Pulawy, 54, 75–80.
18. Sandula J, Machova E and Hribalova V, 1995. Mitogenic activity of particulate yeast beta-(1–>3)-D-glucan and its water-soluble derivatives. International Journal of Biological Macromolecules, 17, 323–326.
19. Seljelid R, Bögwald J and Lundwall Å, 1981. Glycan stimulation of macrophages in vitro. Experimental Cell Research, 131, 121–129.
20. Tzianabos AO, 2000. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clinical Microbiology Reviews, 13, 523–533.
21. Vetvicka V, Terayama K, Mandeville R, Brousseau P, Kournikakis B and Ostroff G, 2002. Pilot study: Orally-administered yeast β1,3-glucan prophylactically protects against anthrax infection and cancer in mice. Journal of the American Nutraceutical Association, 5, 5–9.
22. Volman JJ, Ramakers JD and Plat J, 2008. Dietary modulation of immune function by beta-glucans. Physiology and Behavior, 94, 276–284.
23. Wójcik R, 2010. Effect of Biolex Beta-HP on phagocytic activity and oxidative metabolism of peripheral blood granulocytes and monocytes in rats intoxicated by cyclophosphamide. Polish Journal of Veterinary Sciences, 13, 181–188.
24. Zekovic DB, Kwiatkowski S, Vrvic MM, Jakovljevic D and Moran CA, 2005. Natural and modified (1–>3)-beta-D-glucans in health promotion and disease alleviation. Critical Reviews in Biotechnology, 25, 205–230.